Trial Profile
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenously Administered LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia on Stable Doses of Statin Medications
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs LGT 209 (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Novartis
- 23 Nov 2013 New trial record